Longer tamoxifen use helps stave off breast cancer; Caraco, DUSA win antitrust nod for buyout;

@FiercePharma: Teva investors want new CEO Jeremy Levin to say he has their back in next week's analyst presentation. News | Follow @FiercePharma

> Ten years of breast cancer treatment with tamoxifen beat the standard 5 years at stopping recurrence and cutting the death rate, without a big increase in the risk of endometrial cancer. Report (sub. req.)

> Caraco Pharmaceutical, the U.S. unit of India's Sun Pharmaceutical Industries, won early approval for its buyout of DUSA Pharmaceuticals. Report

> India is looking at exporting more drugs to Iran to help alleviate shortages there. Report

> Pfizer ($PFE) agreed to allow its Elelyso partner Protalix BioTherapeutics to continue managing ongoing clinical trials of the drug, while Pfizer will handle new trials. Report

> Researchers say coatings on aspirin tablets may be responsible for some patients' less-than-adequate response to daily low-dose therapy. Report

Medical Device News

 @FierceMedDev: Industry groups urge Congress to delay device tax. Story | Follow @FierceMedDev

@MarkHFierce: Research at Columbia proposes the use of a prenatal genetic test as standard of care--it's much more comprehensive. Item | Follow @MarkHFierce

 @DamianFierce: In case you missed it, we rounded up some industry reaction to the final medical device tax regs. Story | Follow @DamianFierce

> Many hospitals don't protect devices from hackers, study says. Story

> Study: ICDs mar kids' quality of life. Report

Biotech News

 @FierceBiotech: Eli Lilly touts antibody that reverses symptom of Alzheimer's. News | Follow @FierceBiotech

@JohnCFierce: Biotech upstart Moderna nails down $40M for bold RNA idea. Article | Follow @JohnCFierce

 @RyanMFierce: FDA is on track to increase new drug approvals again. But is it enough? Story (sub. req.) | Follow @RyanMFierce

> FDA matches most new drug approvals in years in 2012; Is it enough? Report

> Against tough odds, Lundbeck touts high-stakes R&D end game. Story

> Biotech upstart Moderna nails down $40M for bold RNA idea. Article

Vaccines News

 @AlisonBFierce: FhCMB lands up to $9.9M from NIH for anthrax vaccine research. More | Follow @AlisonBFierce

> Flu season arrives a month early. Item

> DARPA tackles the DNA vaccine. Article

> Protein Sciences expands flu vaccine operations to Pfizer site. More

> Altravax lands $3.45M from NIH for HIV vaccine research. News

> Sanofi Pasteur nabs Menactra expansion in Canada. Story

Pharma Manufacturing News

 @EricPFierce: Happy Holidays from FDA. It extends to Dec. 18 the deadline to register API and generic drug manufacturing plants. More | Follow @EricPFierce

> Sun setting on Sunovion Canadian API plant. Article

> Cargo theft law puts target on organized crime. News

> Lilly taps Strides, Agila for cancer med manufacturing. Story

> FDA registration deadline looms for generic drugmakers. Report

And Finally... Novo Nordisk ($NVO) has launched the world's first all-diabetic cycling team, which comprises 17 riders from around the world. Report

 

Suggested Articles

Cannes Lions Health kicks off Monday, and attendees are looking for some breakouts—leading-edge tech, creativity and inspiration, for instance.

Bluebird has priced gene therapy Zynteglo at €1.575 million in Europe and promised a U.S. price in “reasonably close” range.

Generic pain drug maker Lannett is closing its plant in Wyoming and laying off the remaining 80 employees.